Transplant Immunobiology Research

Dr. Satish Nadig

Lee Patterson Allen Transplant Immunobiology Laboratory

The research focus of the Lee Patterson Allen Transplant Immunobiology Laboratory is dedicated  to investigating novel innovations in transplant research. As a comprehensive research enterprise, we are interested in all aspects of transplantation spanning donor organ management to the induction of allograft tolerance. In addition, we are also investigating techniques that will lead to the next era of transplantation including bioengineering and artificial tissue development. 

The Transplant Research and ImmunoBiology Institute (TRII) was formalized in 2019 and encompasses both clinical research in the Transplant Clinical Research Core (TCRC) and basic/translational research in both the Lee Patterson Allen Transplant ImmunoBiology Laboratory(TIBL) and the ImmunoEngineering Core.

Additionally, the TRII is a comprehensive federally and privately funded institute that also engages the Center for Cellular Therapy and the Foundation for Research and Development for all aspects of transition of therapeutics to patient care.

The Patterson Barclay Memorial Foundation was instrumental in the development of the TIBL and formalization of the entire institute. Dr. Satish Nadig serves as the institute scientific director and Drs. David Taber, Carl Atkinson, and Michael Yost serve as directors to the TCRC, TIBL and the ImmunoEngineering Cores respectively. The TRII has partnered with various industries (both domestic and international) to move transplant-related therapeutics closer to the bedside. Recently, these industry ties have led to the TRII focusing on COVID-related therapeutics as well.

Dr. Konrad Rajab’s laboratory focuses on unsolved problems in congenital cardiac surgery and has a strong translational emphasis. It forms an integral part of the Lee Patterson Allen Transplant Immunobiology Laboratory (directed by Dr. Satish Nadig), but is highly collaborative within the interdisciplinary MUSC community and beyond. Current projects in the lab include the development of a new operation, understanding the immune privilege of heart valves, and medical device development. This work has resulted in numerous publications and patent applications.

International Partnerships:

Pandorum Technologies, Pvt. Ltd. and the Transplant Research and ImmunoBiology Institute (TRII) along with the Center for Cellular Therapy (CCT) have partnered to push forward bioengineered tissues and cellular therapies in the treatment of diseases spanning corneal wound healing and COVID-related lung disease. These translational activities have utilized the strengths of MUSC's Department of Surgery bench-to-bedside culture.

The TRII along with the CCT at MUSC have been a ‘one stop shop’ for an aspiring start-up like Pandorum Technologies, operating in the field of tissue engineering and regenerative medicine, in the journey to clinical translation of its novel therapies developed to serve patients with unmet clinical needs.The team and the infrastructure at MUSC have been critical for the formulation optimization, cGMP grade material production, clinician study design, execution,and guidance through clinical regulatory approval maintaining global standards with ‘patients first’ in mind- driven by precise decision making and fast execution atan affordable cost.

We are looking forward to an exciting journey ahead.

Tuhin Bhowmick, Ph.D.
Co-founder, CEO
Pandorum Technologies Pvt. Ltd.

Surgical Outcomes Research and Innovation Nucleus (SORIN)

The Surgical Outcomes Research and Innovation Nucleus (SORIN) was formalized in 2019 and serves to foster the development, testing and implementation of innovative therapeutic and health services interventions aimed at improving outcomes in patients undergoing surgery at MUSC.

SORIN has a diverse and active portfolio of clinical research endeavors, including nearly 50 ongoing clinical trials across all surgical disciplines housed within the Department of Surgery. We actively follow nearly 600 patients enrolled in our trials. We are currently testing new drug therapies, devices and cellular-based interventions designed to improve and extend the lives of South Carolinians seeking surgical care within our institution. Embedded within SORIN and an arm of the Transplant Research and ImmunoBiology Institute (TRII) is the Transplant Clinical Research Core (TCRC). 

Transplant Clinical Research Core (TCRC)

The main function of the TCRC is to facilitate the benchtop-to-bedside concept within organ transplantation by streamlining the process of innovative therapies moving from the laboratory to clinical trials and use within usual care. The TCRC is led by David J. Taber, Pharm.D., BCPS, whose current research endeavors surround the study of optimizing medication utilization in transplantation and studying mechanisms to improve the peri-operative value of care in transplant surgery.

Improving Surgical Outcomes Through Disparities Research

Investigators within the Department of Surgery are nationally recognized in studying the causes and consequences of healthcare disparities in vulnerable patient populations; most notably African Americans.

Our researchers are conducting pioneering interventional studies with the goal of reducing the impact of race and socioeconomic status on health outcomes.

Within our clinical trials, we have a strong track record of enrolling patients that are underrepresented in research. Often these patient populations are missing in clinical trials and inclusion is of paramount importance to providing best clinical outcomes to all populations.We strive to include a highly diverse patient population in all of our clinical trials in transplantation. Many of our other clinical trials, including oncology, cardiac surgery and acute care surgery clinical trials, have similarly diverse populations.

Research Scientists

David J. Taber, Pharm.D., BCPS: Dr. Taber's research focuses on optimizing transplant medication safety through Pharmacist-led mHealth based intervention. He is the PI of a $1,492,135 R18 study with the U.S. Department of Health & Human Services, Agency for Healthcare Research and Quality (AHRQ) 

John McGillicuddy, M.D.: Dr. McGillicuddy's research focuses on research to increase kidney transplant recipient graft survival. Dr.McGillicuddy is the PI of a $1.11 million National Institutes of Health grant to examine a novel use of mobile health technology to reduce kidney transplant recipient premature graft loss.

Research on PubMed

South Carolina Investigators in Transplantation: The South Carolina Investigators in Transplantation (SCIT) is comprised of a group of basic science and translational investigators whose laboratories have a specific focus in transplant immunology. 

MUSC Pediatric Transplant Program: The MUSC Health Transplant Center offers the most advanced pediatric transplant resources, facilities, and physicians skilled in the latest techniques, all focused on saving and improving the quality of young lives.